

# Ekso Bionics Files a Shelf Registration Statement With SEC

RICHMOND, Calif., June 23, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission ("SEC"). When declared effective by the SEC, the registration statement will allow Ekso Bionics to issue various types of securities, including common stock, preferred stock, warrants, units and/or rights to purchase any of these securities, from time to time in one or more offerings up to an aggregate amount of \$75 million.

"We believe filing a shelf registration is a prudent step to provide additional financial flexibility for us and one we have indicated we would take," said Nathan Harding, co-founder and chief executive officer of Ekso Bionics. "We anticipate that a shelf registration will increase our ability to access the capital markets and allow Ekso Bionics to respond strategically to meet our growth objectives."

After the shelf registration statement becomes effective, Ekso Bionics may offer and sell securities covered by the registration statement through one or more methods of distribution, subject to market conditions and Ekso Bionics' capital needs. The terms of any offering under the shelf registration statement will be established at the time of such offering and will be described in a prospectus supplement filed with the SEC prior to completion of the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any offering of the securities covered under the shelf registration statement will be made solely by means of a prospectus and an accompanying prospectus supplement relating to that offer.

Ekso Bionics has been updating their website with company information on an ongoing basis and will continue to do so. As a recognized channel to disseminate financial, regulatory and product information we encourage our various stakeholders to check our website frequently for updates.

## About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve

the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at [www.eksobionics.com](http://www.eksobionics.com)

Facebook: [www.facebook.com/eksobionics](http://www.facebook.com/eksobionics)

Twitter: [@eksobionics](https://twitter.com/eksobionics)

YouTube: <https://www.youtube.com/user/EksoBionics/>

## **Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at [www.eksobionics.com](http://www.eksobionics.com). The Company does not undertake to update these forward-looking statements.

### **CONTACT: Media Contact:**

Heidi Darling, Director of Marketing Communications  
Phone: 510-984-1761 x317  
E-mail: [hdarling@eksobionics.com](mailto:hdarling@eksobionics.com)

### **Investor Contact:**

Chad Rubin, Senior Vice President  
Phone: 646 378-2947  
E-mail: [crubin@troutgroup.com](mailto:crubin@troutgroup.com)

Source: Ekso Bionics

